PARP Inhibitors in Oncology
Poly (ADP-ribose) polymerase (PARP) enzymes play important roles in the repair of single-strand breaks (SSBs) in DNA. SSBs occur from environmental agents, spontaneous DNA bond disruption, or normal DNA metabolism. PARP1 binds to DNA following SSB and recruits other enzymes to repair the DNA damage.
Since hitting the market in 2015, drugs that target poly (ADP-ribose) polymerase (PARP) have transformed the clinical management of cancers harboring BRCA-mutations. There are three approved PARP inhibitors and five pipeline therapies in Phase II and Phase III clinical development. While the majority of trials are focused on ovarian and breast cancer, makers of pipeline therapies are seeing a saturated market and turning towards prostate, pancreatic, and other cancers.
As more PARP inhibitors have been commercialized, drug developers are turning their attention towards broadening drug labels and exploring combination strategies. With greater emphasis being placed on combinations with PD-1/PD-L1 inhibitors in breast cancer, as well as combinations with chemotherapy in ovarian, breast, prostate, and other cancers.
The report PARP Inhibitors in Oncology, covers the management of PARP inhibitors in the US, Europe, and Asia, focusing on efficacy and safety comparisons for approved products, current and future indications, and research and development strategies.
Companies Mentioned: AbbVie, AstraZeneca, BeiGene, Clovis Oncology, Jiangsu Hengrui Medicine Co., Merck, Nerviano Medical Sciences, Oncology Venture, Pfizer, Sanofi, SyntheX, Tesaro
This report combines key opinion leader insight with in-house analyst expertise and research to provide an insight-rich look at PARP inhibitors in the US, Europe, and Asia. Components of the report includes -
Reasons to buy
- Overview of PARP Inhibitors in Oncology: Background, mechanism of action, and clinical development of PARP inhibitors.
- Epidemiology Analysis: Which current and future disease spaces are relevant to PARP inhibitors.
- Marketed PARP Inhibitors: How the currently approved PARP inhibitors compare.
- Pipeline Assessment in the 8MM: What are the pipeline PARP inhibitor products in development in oncology.
- Key Players: What companies are developing PARP inhibitors in oncology.
- Research and Development Strategies: How are PARP inhibitor clinical trials being designed, and what combination strategies are being explored in the US, Europe, and Asia.
- Pricing, Reimbursement, and Regulatory Strategies: What current and future challenges face PARP inhibitors from a payer’s perspective.
- Develop business strategies by understanding the trends shaping and driving the PARP inhibitor market in the US, Europe, and Asia.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the portfolios of various competitors.
- Identify areas of unmet need within the PARP inhibitor market to help drive research and development towards future market opportunities.
- Gain insights to help plan and design your clinical trials.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Identify key pricing and reimbursement strategies.
- 1. Preface
- 1.1 Table of Contents
- 1.2 Abbreviations
- 1.3 Related Reports
- 1.4 Upcoming Related Reports
- 2. Executive Summary
- 2.1 Key Findings
- 2.2 KOL Insight on PARP Inhibitor Competitive Landscape
- 3. Overview - PARP Inhibitors
- 3.1 The Role of PARP in DNA Repair
- 3.2 Mechanism of PARP Inhibitors in Cancer
- 3.3 History of PARP Inhibitor Clinical Development
- 3.4 PARP Inhibitors in Ovarian Cancer
- 3.5 PARP Inhibitors in Breast Cancer
- 3.6 PARP Inhibitors in Prostate Cancer
- 3.7 PARP Inhibitors in Pancreatic Cancer
- 3.8 PARP Inhibitors in Other Cancers
- 3.9 PARP Inhibitor Resistance and Long-Term Effects
- 4. Epidemiology Analysis
- 4.1 Epidemiology Analysis - Ovarian Cancer
- 4.2 Epidemiology Analysis - Breast Cancer
- 4.3 Epidemiology Analysis - Prostate Cancer
- 4.4 Epidemiology Analysis - Pancreatic Cancer
- 4.5 Epidemiology Analysis - Gastric Cancer
- 5. Marketed PARP Inhibitors
- 5.1 Timeline of PARP Inhibitors Clinical Development in the 8MM
- 5.2 Currently Marketed PARP Inhibitors in Oncology
- 5.3 KOL Input on Marketed PARP Inhibitors
- 6. Pipeline Assessment in the 8MM
- 6.1 Assessment of Ongoing Trials of Marketed PARP Inhibitors
- 6.2 Talazoparib (Pfizer)
- 6.3 Veliparib (AbbVie)
- 6.4 Pamiparib (BeiGene)
- 6.5 2X-121 (Oncology Venture)
- 6.6 Fluzoparib (Jiangsu Hengrui Medicine Co.)
- 6.7 PARP Trapping
- 6.8 KOL Input on Pipeline PARP Inhibitors
- 7. Key Players
- 7.1 Companies Developing PARP Inhibitors in Oncology
- 7.2 Analysis of the Company Portfolio Gap in PARP Inhibitors
- 7.3 KOL Input on Key Players
- 8. Clinical Trials Mapping and Design
- 8.1 Ongoing Clinical Trials of PARP Inhibitors Pipeline
- 8.2 KOL Input on Challenges in PARP Inhibitor Clinical Trial Design
- 9. Combination Strategies with PARP Inhibitors
- 9.1 Overview of Clinical Trials of PARP Inhibitors as Combination Therapy
- 9.2 Combination Strategy of PARP Inhibitors with Immunooncology
- 9.3 Combination Strategy of PARP Inhibitors with Angiogenesis Inhibitors
- 9.4 Combination Strategy of PARP Inhibitors with Chemotherapy
- 9.5 Combination Strategy of PARP Inhibitors with Other Drugs
- 10. Pricing, Reimbursement, and Regulatory Strategy
- 10.1 Current Strategies for Oncology Products
- 10.2 Differentiating Between Lynparza, Rubraca, and Zejula
- 10.3 Future PARP Inhibitors
- 10.4 PARP Inhibitor Challenges from US/UK Payers’ Perspective
- 11. Market Outlook and Future Use
- 11.1 Market Outlook
- 11.2 Anticipated Key Events in PARP Inhibitors
- 11.3 Future Uses of PARP Inhibitors in Oncology
- 12. Appendix
- 12.1 Sources
- 12.2 Methodology
- 12.3 Primary Research
- 12.4 About the Authors
- 12.5 About GlobalData